Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 112 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Holidays, Traditions and Grief December 21, 2020 PDX Mouse Models Are Reliable Stand-Ins for Human Tumors, Study Finds February 2, 2021 Bowel scope screening to stop in England January 14, 2021 After a Breast Cancer Diagnosis, Men May Be More Likely to... October 2, 2019 Load more HOT NEWS People With Certain Cancers Are Almost Three Times As Likely To... Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... Mammograms Can Detect COVID-19 Vaccination Swelling, Causing Cancer Scares Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life
